Bayer is making remarkable strides in its pharmaceutical growth strategy, fueled by a wave of innovative advancements and strong progress in its drug pipeline. Regulatory submissions are underway for new treatments that promise to address critical health challenges, including a third indication for darolutamide in prostate cancer, finerenone for a common type of heart failure, and acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM). These developments reaffirm Bayer’s leadership in these crucial therapeutic areas.
Adding to this momentum, Bayer announced at the 43rd J.P. Morgan Healthcare Conference in San Francisco that it is also advancing its work in women’s health, radiology, and Parkinson’s disease treatments.
“We are successfully delivering on our ambitious goals despite the challenges we face,” said Stefan Oelrich, Member of Bayer’s Board of Management and President of its Pharmaceuticals Division. “Our pipeline is growing stronger as we accelerate breakthrough innovations, powered by a new operating model that drives both growth and efficiency.”
Bayer continues to solidify its leadership in prostate cancer treatment with plans to launch a third indication for darolutamide (Nubeqa™) by 2025. The treatment has shown strong results in multiple trials and achieved blockbuster status, crossing one billion euros in annual sales in 2024. With over 100,000 patients treated globally, Nubeqa™ is now the fastest-growing androgen receptor inhibitor in the U.S.
In cardiovascular health, Bayer’s finerenone (Kerendia™) has demonstrated promising results in heart failure patients and is on track for a potential market launch by late 2025. Meanwhile, acoramidis has shown exceptional efficacy in stabilizing transthyretin amyloid cardiomyopathy (ATTR-CM) and is awaiting EU approval, which could pave the way for better treatment options for this challenging condition.
In women’s health, Bayer is set to transform menopause management with elinzanetant, a non-hormonal treatment for hot flashes. The therapy has achieved positive results across multiple Phase III trials, showing significant improvements in symptoms, sleep, and quality of life. With global regulatory submissions under review, Bayer is poised to launch this groundbreaking treatment in 2025.
Bayer is also driving innovation in radiology with its investigational MRI contrast agent gadoquatrane, which achieved promising results in the Phase III QUANTI program. This success underscores Bayer’s commitment to advancing medical imaging technology.
In neurology, Bayer is breaking new ground in Parkinson’s disease treatments. Its investigational stem cell-based therapy, bemdaneprocel, is moving directly to Phase III trials, and gene therapy candidate AB-1005 is advancing in a Phase II study. These therapies represent hope for patients battling this progressive disease.
Bayer’s oncology pipeline is flourishing with precision medicine approaches, including targeted therapies for lung cancer and new radionuclide treatments for prostate cancer. Bayer’s recent acquisition of Tavros Therapeutics strengthens its ability to develop precision small-molecule therapies for previously undruggable cancer targets.
With bold investments and a clear focus on areas of high unmet need, Bayer is not just advancing its pharmaceutical pipeline—it is redefining the future of healthcare, offering new hope to patients and strengthening its position as a global leader in medicine.
